Concomitant use of selective serotonin reuptake inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: How often does it really happen?

Journal of Affective Disorders

Volumn 46, Issue 1, 1997, Pages 59-67

  Gregor, Karl J ^a   Way, Karen ^a   Young, Christopher H ^a   James, Steven P ^a  

^a PCS Health Systems Incorporated   (United States)

Author keywords

Concomitant use; Cytochrome P450; Drug interactions; Drug utilization; Selective serotonin reuptake inhibitors

Indexed keywords

AMIODARONE; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ASTEMIZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLOMIPRAMINE; CYTOCHROME P450 ISOENZYME; DESIPRAMINE; DILTIAZEM; ERYTHROMYCIN; FELODIPINE; IMIPRAMINE; METOPROLOL; MEVINOLIN; NEFAZODONE; NEUROLEPTIC AGENT; NIFEDIPINE; NORTRIPTYLINE; PROPAFENONE; PROPRANOLOL; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; TERFENADINE; TIMOLOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VERAPAMIL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG METABOLISM; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY;

1-NAPHTHYLAMINE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FLUOXETINE; HUMANS; LIVER; METABOLIC CLEARANCE RATE; MIXED FUNCTION OXYGENASES; PAROXETINE; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 0030734303     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(97)00080-3     Document Type: Article

References (8)

1. Depression Guideline Panel, 1993a. Depression in Primary Care: Volume 1. Detection and Diagnosis. Clinical Practice Guideline, Number 5. Rockville, MD. U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 93-0550.
2. Depression Guideline Panel, 1993b. Depression in Primary Care: Volume 2. Treatment of Major Depression. Clinical Practice Guideline, Number 5. Rockville, MD. U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 93-0551.
3. Devane, C.L., 1995. SSRIs and Cytochrome P450 Mediated Drug Interactions. Presented at the Southwest Regional Psychiatric Pharmacology Update, Scottsdale, AZ, November 4-5.
4. Facts and Comparisons, Inc., 1996. Drug Facts and Comparisons. St. Louis, MO.
5. Farris, K.B., Kaplan, B., Kirking, D.M., 1994. Examination of days supply in computerized prescription claims. J. Pharmacoepidemiol. 3 (1), 63-76.
6. Gregor, K.J., Riley, J.A., Downing, D.K., 1996. Concomitant use of anxiolytics and hypnotics with selective serotonin reuptake inhibitors. Clin. Ther. 18 (3), 521-527.
7. Nemeroff, C.B., DeVane, C.L., Pollock, B.G., 1996. Newer antidepressants and the cytochrome P450 system. Am. J. Psychiatry 153 (3), 311-320.
8. Riesenman, C., 1995. Antidepressant drug interactions and the cytochrome P450 system: A critical appraisal. Pharmacotherapy 15 (6 Pt 2), 84S-99S.